Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 3802 clinical trials
Featured trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by

  • 16 views
  • 28 Oct, 2022
  • 32 locations
Featured trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease (INVOKE-2)

A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.

amyloidosis
mini-mental state examination
alzheimer's disease
  • 8 views
  • 14 Sep, 2022
  • 76 locations
Featured trial
  • 10 views
  • 23 Oct, 2022
  • 80 locations
Featured trial
Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2).

This study is a Phase 3 global, multicenter, placebo-controlled double-blind randomized study that will enroll participants with inoperable locally recurrent or metastatic SCAC not previously

  • 1245 views
  • 23 Oct, 2022
  • 84 locations
Featured trial
A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson's Disease (PADOVA)

This is a multicenter, randomized, double-blind, placebo-controlled study that will evaluate the efficacy and safety of intravenous (IV) prasinezumab versus placebo in participants with Early

dopamine transporter
resting tremor
bradykinesia
SPECT Scan
early parkinson's
  • 160 views
  • 28 Oct, 2022
  • 104 locations
Featured trial
Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia (PATHWAY) (PATHWAY)

The purpose of this study is to evaluate the efficacy and safety of parsaclisib compared with placebo in participants with Primary Warm Autoimmune Hemolytic Anemia (wAIHA),

  • 11 views
  • 11 Nov, 2022
  • 39 locations
Featured trial
Study to evaluate HZN-825 in patients with Idiopathic Pulmonary Fibrosis (IPF)

The goal is to determine the efficacy, safety and tolerability for 360 patients with Idiopathic Pulmonary Fibrosis (IPF) assigned to either one of 2 dose regimens of HZN-825 (administered once daily (QD) or twice daily (BID)) or a placebo regimen for 52 weeks. Participants who complete the duration of this …

emphysema
pneumonia
diffusion capacity of the lung for carbon monoxide
  • 10 views
  • 18 Oct, 2022
  • 53 locations
Featured trial
Dupilumab in Allergic Fungal Rhinosinusitis (AFRS) (LIBERTY-AFRS-AI)  

Primary Objective: To evaluate the ability of dupilumab to reduce the need for rescue therapy with systemic corticosteroids (SCS) or surgery of AFRS in patients with AFRS who previously have had sino-nasal surgery Secondary Objectives: To evaluate the efficacy of treatment with dupilumab to reduce sinus opacification in a population …

  • 89 views
  • 27 Jan, 2023
  • 41 locations
Featured trial
Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus (APATURA)

This is a multinational, randomized, placebo-controlled, parallel treatment, Phase 2, double-blind, 2 arm study evaluating the efficacy and safety of SAR441344 in comparison with placebo in

rash
arthritis
lupus
antinuclear antibody
  • 10 views
  • 25 Jan, 2023
  • 6 locations
Featured trial
A trial evaluating TEPEZZA® in Patients With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

The overall objective is to investigate the safety, tolerability and effect on insulin-like growth factor-1 (IGF-1), inflammatory and fibrotic biomarkers of TEPEZZA® administered once every 3 weeks (q3W) for 24 weeks in the treatment of participants with diffuse cutaneous systemic sclerosis (dcSSc).

  • 6 views
  • 11 Aug, 2022
  • 5 locations